AI assistant
Sending…
Nuvectis Pharma, Inc. — Director's Dealing 2022
Nov 30, 2022
33912_dirs_2022-11-30_96883c7a-6636-49ce-be58-08e0e39fd402.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2022-11-30
Reporting Person: BENTSUR RON (Director, Chairman & CEO, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-11-30 | Common Stock | P | 150 | $7.45 | Acquired | 3015459 | Direct |
Footnotes
F1: Includes 96,759 shares of restricted stock and 120,000 restricted stock units.
More from Nuvectis Pharma, Inc.
Interim / Quarterly Report
2026
May 5
Earnings Release
2026
May 5
Regulatory Filings
2026
Feb 23
Capital/Financing Update
2026
Feb 13
Earnings Release
2026
Feb 11
Annual Report
2026
Feb 11
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9